Oncology

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company
developing targeted therapies to redefine treatment for biomarker-specific patient
populations. Driven by a commitment to rigorous science and a passion for improving the
lives of people impacted by cancer and other life-threatening diseases, Calithera is
advancing a robust pipeline of investigational, small molecule oncology compounds with a
biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new
therapies for patients suffering from aggressive hematologic and solid tumor cancers for
which there are currently limited treatment options.

In October 2021, Calithera acquired from Takeda two promising clinical-stage compounds
that have demonstrated single-agent clinical activity with the greatest potential in
biomarker-defined cancer-patient populations. This was a transformative transaction that
aligns with Calithera’s focus and deep expertise in targeted, small-molecule cancer
therapies.

• Sapanisertib (CB-228) is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
• Mivavotinib (CB-659) is a SYK inhibitor that targets the constitutively active BCR pathway in many non-Hodgkin’s lymphoma (NHL) cases as well as the constitutively active inflammatory signaling pathway in MyD88-mutated NHL.

Our near-term clinical development plans include leveraging our clinical and biomarker expertise in the KEAP1/NRF2 pathway by developing inhibitor sapanisertib in squamous non-small cell lung cancer, and advancing the development of mivavotinib in specific biomarker-defined populations of diffuse large B-cell lymphoma, or DLBCL. By focusing on well-characterized genetic vulnerabilities with molecules that have already shown single-agent activity, we will be able to generate phase 2 data with targeted, efficient study designs.